key: cord-0850070-40aye6tg
authors: Imai, Kazuo; Matsuoka, Masaru; Tabata, Sakiko; Kitagawa, Yutaro; Nagura-Ikeda, Mayu; Kubota, Katsumi; Fukada, Ai; Takada, Tomohito; Sato, Momoko; Noguchi, Sakiko; Takeuchi, Shinichi; Arakawa, Noriaki; Miyoshi, Kazuyasu; Saito, Yoshiro; Maeda, Takuya
title: Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severity
date: 2021-08-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.08.026
sha: 5ff2b13612955ea703a382fc9f23001659b3f9be
doc_id: 850070
cord_uid: 40aye6tg

BACKGROUND: We evaluated the cross-reactive antibody response against seasonal human coronaviruses (HCoVs) according to disease severity in patients with COVID-19 in Japan. METHODS: We analyzed 194 paired-collected serum samples from 97 patients with COVID-19 (mild, 35; severe, 62) on admission and during convalescence. IgG antibodies against the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2 and four seasonal HCoVs (HCoV-NL63, -229E, -OC43, and -HKU1) were detected by enzyme-linked immunosorbent assays. RESULTS: There was no difference in optical density (OD) values for seasonal HCoVs on admission between the severe and mild cases. In addition, a specific pattern of disease severity-associated OD values for HCoVs was not identified. A significant increase of OD values from admission to convalescence for HCoV-HKU1and -OC43 IgG-S and HCoV-NL63 and -229E IgG-N was observed in the severe cases. Significant differences were observed between the mild and severe cases for HCoV-HKU1 and -OC43 IgG-S OD values during convalescence. Correlations were found between the fold-change of HCoV-OC43 IgG-S OD values with the fold-change of SARS-CoV-2 IgG-S OD values and C-reactive protein, lactate dehydrogenase, and lymphocyte levels. CONCLUSIONS: There was no association between the antibody titer of seasonal HCoVs in the early phase of COVID-19 and disease severity.

Novel coronavirus disease 2019 (COVID- 19) , which is caused by the lineage B betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing pandemic worldwide . An understanding of the humoral immune response against SARS-CoV-2 is important for assessing the potential for viral re-infection, diagnosis, surveillance, and pathogenesis. SARS-CoV-2 contains four major structural proteins, including the spike (S), membrane (M), and envelope (E) proteins that form the viral envelope, and the nucleocapsid (N) protein, which is located in the ribonucleoprotein core.

The S protein, which consists of two subunits (S1 and S2), is responsible for recognition of the host cellular receptor to initiate virus entry (Cui et al., 2019) . In addition, SARS-CoV-2 encodes 16 non-structural proteins and nine accessory proteins (Dai and Gao, 2021) . The S and N proteins are highly immunogenic for humoral responses, whereas the M and E proteins are poorly immunogenic (Du et al., 2008 , Long et al., 2020 . Therefore, S and N are considered the main antigens of SARS-CoV-2. Nowadays, the humoral immune response of patients with COVID-19 continues to be clarified by the efforts of the worldwide scientific community (Imai et Four seasonal HCoVs (HCoV-NL63, -229E, -OC43, and -HKU1) have been identified as human pathogens. Seasonal HCoVs cause respiratory tract infections in humans, are detected frequently in winter, and are responsible for 15-30% of common colds worldwide (Liu. et al., 2020b) . Seasonal HCoVs belong to two distinct taxonomic genera:

HCoV-NL63 and -229E belong to the alphacoronavirus family; HCoV-OC43 and HCoV-HKU1 belong to the betacoronavirus family (Liu. et al., 2020b) . Protein homology between SARS-CoV-2 and seasonal HCoV antigens is approximately 19.8% for S1, 39.9% for S2, and 33.0% for N (Saletti et al., 2020) . Potential cross-reactivity of immunity between SARS-CoV-2 and seasonal HCoVs has been reported, but it is unknown whether the humoral immunity induced by previous infections of seasonal HCoVs and during convalescence (at ≥18 days after initial symptom onset) from each patient. Briefly, the median period from initial symptom onset to admission was 8 days (IQR, 7-13 days) and 20 days (IQR, 18-24 days) to convalescence. All serum samples were stored at −80°C.

For the initial diagnosis of COVID-19, RT-qPCR and RT-LAMP were performed 

To measure IgG antibody titers against the N and S antigens of SARS-CoV-2, a QuaResearch COVID-19 Human IgM IgG ELISA Kit (Nucleocapsid Protein) (RCOEL961N; Cellspect Co., Ltd., Iwate, Japan) and QuaResearch COVID-19 Human IgM IgG ELISA Kit (Spike Protein) (RCOEL961; Cellspect Co., Ltd.) were used, respectively. Serum samples were diluted 1:1,000 for ELISA for the N antigen and 1:250 for ELISA for the S antigen in 1% bovine serum albumin/PBS with Tween 20 (PBS-T). For the assay, 100 µL diluted serum samples were added to each well. After incubation at room temperature for 1 h, the plates were washed three times with PBS-T. Specific antibodies were detected with 100 µL horseradish peroxidase-conjugated anti-human IgG at room temperature for 1 h, after which the plates were washed three times with PBS-T. The enzymatic reaction was developed with 100 µL TMB substrate at room temperature for 10 min. Afterwards, the reaction was stopped using 100 µL of 1 M HCl and the plates were read at 450 nm using an ELISA reader. The experiments were performed at Cellspect Co., Ltd.

The S and N proteins of each HCoV (HCoV-HKU1, -OC43, -NL63, and -229E) were obtained from Sino Biological, Inc. (Beijing, China). Details of the antigens used in this study are shown in Supplemental Table 1 . Microplates (Corning, Steuben, NY) were coated with 100 µL carbonate-bicarbonate buffer (0.05 M, pH 9.6) with the S or N antigen of each HCoV (Sino Biological, Inc.) at an optimal concentration of 50 ng/well. After incubation overnight at 4°C, the plates were washed three times with PBS-T and blocked with 200 µL PBS with 1% Block Ace (KAC Co., Ltd., Kyoto, Japan), a milk protein-based blocking reagent, at 37°C for 1 h. Upon drying overnight at 50°C, the plates were sealed and stored at 4°C until use. For the assay, human serum was diluted 1:100 in PBS containing 1% Block Ace, and 100 µL of each sample was added to the well. After incubation at 37°C for 1 h, the plates were washed three times with PBS-T and specific antibodies were detected with 100 µL horseradish peroxidase-conjugated mouse anti-human IgG (catalog no. 109-035-088; Jackson ImmunoResearch Laboratories, Inc., Sacramento, CA) diluted 1:20,000 in PBS with 1% Block Ace at 37°C for 1 h. The plates were washed three times with PBS-T and the enzymatic reaction was developed with 100 µL/well solution from a TMB Peroxidase EIA Substrate Kit (Bio-Rad, Hercules, CA) at 37°C for 30 min. Afterwards, the reaction was stopped using 100 µL of 2 N H 2 SO 4 /well and the plates were read at 450 nm using an ELISA reader.

Viral RNA was extracted from nasopharyngeal specimens homogenized in PBS 

All serum samples were evaluated by ELISA in triplicate and the average optical density (OD) value for these measurements was defined as the test result. Fold-change was determined by measuring the fold-change in OD values in IgG antibody recognition between two subsequent paired specimens collected on admission and during convalescence (OD convalescence / OD admission ). Continuous variables were expressed as the mean and standard deviation or median and IQR, and compared using the t-test or Wilcoxon rank-sum test for parametric or non-parametric data, respectively. Linear regression analysis was used to assess the relationship between each continuous variable. Rho values were analyzed by Pearson's correlation coefficient and the Spearman rank-order correlation coefficient for parametric or non-parametric data, respectively. A two-sided p-value < 0.05 was considered statistically significant. All statistical analyses were conducted using R (v 4.0.2; R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).

A total of 194 paired-serum samples from the admission and convalescence phases were collected from 97 patients (mild, 35 patients; severe, 62 patients) and analyzed by ELISAs. SARS-CoV-2 IgG-S (median OD values: admission 0.04 vs. convalescence 0.24, p < 0.001) and IgG-N (admission 0.32 vs. convalescence 2.12, p < 0.001) OD values were significantly higher during convalescence than on admission (Figure 1) . There was no difference in SARS-CoV-2 IgG-S and IgG-N OD values between the severe and mild cases on admission and during convalescence (Figure 1) , whereas fold-changes among paired specimens were higher in the severe cases than in the mild cases (severe vs. mild, p < 0.001) (Figure 2) .

On admission, the rate of patients with OD values > 0.5 for IgG-S and/or IgG-N was 82.5% for HCoV-HKU1, 97.9% for HCoV-OC43, 99.0% for HCoV-NL63, and 99.0% for HCoV-229E. In addition, the corresponding rate for OD values > 1.0 was 45.4% for HCoV-HKU1, 77.3% for HCoV-OC43, 82.5% for HCoV-NL63, and 75.3% for HCoV-229E (Figure 3) . All of the patients showed OD values > 0.5 for IgG-S and/or IgG-N from at least one of the HCoVs. No specific distribution pattern of the seropositive rate for HCoVs was associated with disease severity (Figure 3) .

In the severe cases, HCoV-HKU1 IgG-S (median OD values: admission 0.91 vs. (Figure 1) . There was no significant difference in fold-change among the paired specimens in severe and mild cases (Figure 2) . The correlations between the overall fold-change of antibody levels for seasonal HCoVs and SARS-CoV-2 are shown in Table 1 . Table 1) .

Regression analysis was performed to evaluate the associations between antibody production and clinical characteristics previously associated with severity and mortality in Table 3 ).

Here, we presented the cross-reactivity of antibodies for seasonal HCoVs in patients with COVID-19. Our results suggested that the majority of Japanese COVID-19 patients had antibodies to seasonal HCoVs due to previous infections. However, there was no association between the antibody titer of seasonal HCoVs in the early phase of SARS-CoV-2 infection and the severity of COVID-19. Several antibodies for seasonal HCoVs, especially HCoV-OC43 IgG-S, were increased after SARS-CoV-2 infection in the severe cases, whereas there was no significant change of antibodies for seasonal HCoVs in the mild cases.

In Japan, seasonal epidemics of HCoVs occur mainly in winter, and HCoV-OC43 was detected most frequently in patients with acute respiratory symptoms, followed by As a limitation of the present study, we used serum samples collected during the early phase of COVID-19 symptom onset, and not before SARS-CoV-2 infection. Therefore, the humoral immunity for seasonal HCoVs may be not an exact representation of humoral immunity at the time of SARS-CoV-2 infection. We used only ELISAs to detect the antibodies for seasonal HCoVs; thus, it is possible that the antibody response patterns are assay-specific. Furthermore, the serum samples were collected only from Japanese patients, which may introduce a selection bias because the seroprevalence rate of seasonal HCoVs varies between regions and countries. 

The present study showed there was no association between the antibody titers of seasonal HCoVs during the early phase of COVID-19 with disease severity. Significantly increased OD values for HCoV-HKU1 and -OC43 IgG-S from early symptom onset to the convalescence period were observed in the severe cases, but not in the mild cases. Further investigations are required to determine whether cross-reactivity between SARS-CoV-2 and seasonal HCoV antibodies is associated with the severity of COVID-19.

We thank the clinical laboratory technicians at Saitama Medical University Hospital and the Self-Defense Forces Central Hospital for sample collection, and all members of the COVID-19 Task Force in both hospitals.

The authors report no conflicts of interest relevant to the published work. Blue box, mild cases; red box, severe cases. Black plots indicate the fold-change level of each patient. Adm, admission; conv, convalescence. *p < 0.05, **p < 0.01, and ***p < 0.001. IgG-S, and HCoV-OC43 IgG-S and clinical characteristics. The highest levels during hospitalization were observed for CRP and LDH, and the lowest levels were for lymphocyte counts. Regression analyses were conducted by linear regression. Blue plots, mild cases; red plots, severe cases. Adm, admission; conv, convalescence. *p < 0.05, **p < 0.01, and ***p < 0.001. HCoV-HKU HCoV-NL63 0 62

HCoV-OC43 0 62

HCoV-229E 0 62

Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Origin and evolution of pathogenic coronaviruses

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China

Viral targets for vaccines against COVID-19

Development of subunit vaccines against severe acute respiratory syndrome

Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Added Value of an Oropharyngeal Swab in Detection of Viruses in Children Hospitalized with Lower Respiratory Tract Infection

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

Antibody response patterns in COVID-19 patients with different levels of disease severity-Japan

Antibody-dependent enhancement of severe dengue disease in humans

Seasonality of Human Coronavirus OC43, NL63, HKU1, and 229E Infection in

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses

A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and antibody cross reactions

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Human Coronavirus-229E, -OC43, -NL63, and -HKU1

High neutralizing antibody titer in intensive care unit patients with COVID-19

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serum IgA, IgM, and IgG responses in COVID-19

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 + T Cells in COVID-19

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Incidence and Severity of Covid-19 in Patients with and without Previously Verified Infections with Common Cold Coronaviruses

Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63

Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children

Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Kinetics of viral load and antibody response in relation to COVID-19 severity

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

HCoV-HKU1 HCoV-OC43 HCoV-NL63 HCoV-E229